91 related articles for article (PubMed ID: 11279760)
1. Ivermectin for onchocercal eye disease (river blindness).
Ejere H; Schwartz E; Wormald R
Cochrane Database Syst Rev; 2001; (1):CD002219. PubMed ID: 11279760
[TBL] [Abstract][Full Text] [Related]
2. Ivermectin for onchocercal eye disease (river blindness).
Ejere HO; Schwartz E; Wormald R; Evans JR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
[TBL] [Abstract][Full Text] [Related]
3. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
Abegunde AT; Ahuja RM; Okafor NJ
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
[TBL] [Abstract][Full Text] [Related]
4. Onchocercal eye disease and the impact of Mectizan treatment.
Abiose A
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S11-22. PubMed ID: 9861263
[TBL] [Abstract][Full Text] [Related]
5. Face washing promotion for preventing active trachoma.
Ejere H; Alhassan MB; Rabiu M
Cochrane Database Syst Rev; 2004; (3):CD003659. PubMed ID: 15266493
[TBL] [Abstract][Full Text] [Related]
6. Changes in ocular onchocerciasis after two rounds of community-based ivermectin treatment in a holo-endemic onchocerciasis focus.
Dadzie KY; Remme J; De Sole G
Trans R Soc Trop Med Hyg; 1991; 85(2):267-71. PubMed ID: 1887490
[TBL] [Abstract][Full Text] [Related]
7. Vitrectomy with internal limiting membrane (ILM) peeling versus vitrectomy with no peeling for idiopathic full-thickness macular hole (FTMH).
Spiteri Cornish K; Lois N; Scott N; Burr J; Cook J; Boachie C; Tadayoni R; la Cour M; Christensen U; Kwok A
Cochrane Database Syst Rev; 2013 Jun; (6):CD009306. PubMed ID: 23740611
[TBL] [Abstract][Full Text] [Related]
8. Phacoemulsification with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.
de Silva SR; Riaz Y; Evans JR
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD008812. PubMed ID: 24474622
[TBL] [Abstract][Full Text] [Related]
9. Intra-operative mitomycin C for glaucoma surgery.
Wilkins M; Indar A; Wormald R
Cochrane Database Syst Rev; 2001; (1):CD002897. PubMed ID: 11279773
[TBL] [Abstract][Full Text] [Related]
10. Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus phacoemulsification with posterior chamber intraocular lens for age-related cataract.
Riaz Y; de Silva SR; Evans JR
Cochrane Database Syst Rev; 2013 Oct; (10):CD008813. PubMed ID: 24114262
[TBL] [Abstract][Full Text] [Related]
11. Albendazole for lymphatic filariasis.
Addiss D; Critchley J; Ejere H; Garner P; Gelband H; Gamble C;
Cochrane Database Syst Rev; 2004; (1):CD003753. PubMed ID: 14974034
[TBL] [Abstract][Full Text] [Related]
12. Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone.
Whitworth JA; Gilbert CE; Mabey DM; Maude GH; Morgan D; Taylor DW
Lancet; 1991 Nov; 338(8775):1100-3. PubMed ID: 1682543
[TBL] [Abstract][Full Text] [Related]
13. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
14. Distribution and severity of onchocerciasis in southern Benin, Ghana and Togo.
De Sole G; Accorsi S; Cresveaux H; Remme J; Walsh F; Hendrickx J
Acta Trop; 1992 Dec; 52(2-3):87-97. PubMed ID: 1363185
[TBL] [Abstract][Full Text] [Related]
15. Ivermectin and onchocercal optic neuritis: short-term effects.
Murdoch I; Abiose A; Babalola O; Bird A; Cousens S; Evans J; Jones B
Eye (Lond); 1994; 8 ( Pt 4)():456-61. PubMed ID: 7821473
[TBL] [Abstract][Full Text] [Related]
16. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
[TBL] [Abstract][Full Text] [Related]
17. Audio-visual presentation of information for informed consent for participation in clinical trials.
Ryan RE; Prictor MJ; McLaughlin KJ; Hill SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD003717. PubMed ID: 18254029
[TBL] [Abstract][Full Text] [Related]
18. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss.
Cousens SN; Cassels-Brown A; Murdoch I; Babalola OE; Jatau D; Alexander ND; Evans JE; Danboyi P; Abiose A; Jones BR
Bull World Health Organ; 1997; 75(3):229-36. PubMed ID: 9277010
[TBL] [Abstract][Full Text] [Related]
19. Visual loss in an onchocerciasis endemic community in Sierra Leone.
Whitworth JA; Gilbert CE; Mabey DM; Morgan D; Foster A
Br J Ophthalmol; 1993 Jan; 77(1):30-2. PubMed ID: 8435395
[TBL] [Abstract][Full Text] [Related]
20. Criterion for inclusion in onchocerciasis control programmes based on ivermectin distribution.
De Sole G
Trans R Soc Trop Med Hyg; 1995; 89(2):224-5. PubMed ID: 7778156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
